Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases

Cancer Research

Volumn 60, Issue 11, 2000, Pages 2949-2954

  Boissier, Sandrine ^a   Ferreras, Mercedes ^b   Peyruchaud, Olivier ^a   Magnetto, Sandrine ^a   Ebetino, Frank H ^c   Colombel, Marc ^a   Delmas, Pierre ^a   Delaissé, Jean Marie ^b   Clézardin, Philippe ^a,d  

^a UNIVERSITÉ LYON 1   (France)

^b CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; MATRIX METALLOPROTEINASE; NE 10244; NE 10790; NE 58051; PACLITAXEL; PYRIDINIUM DERIVATIVE; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CARCINOMA; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CLODRONIC ACID; COLLAGEN; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FLOW CYTOMETRY; FLUOROMETRY; HUMANS; IMIDAZOLES; LAMININ; MALE; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PACLITAXEL; PROSTATIC NEOPLASMS; PROTEOGLYCANS; PYRIDINES; PYRIDINIUM COMPOUNDS; TUMOR CELLS, CULTURED; ZINC;

EID: 0034214362     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Mundy, G. R. Mechanisms of bone metastasis. Cancer (Phila.), 80: 1546-1556, 1997.
2. Lipton, A. Bisphosphonates and breast carcinoma. Cancer (Phila.), 80: 1668-1673, 1997.
3. Sasaki, A., Boyce, B. F., Story, B., Wright, K. R., Chapman, M., Boyce, R., Mundy, G. R., and Yoneda, T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res., 55: 3551-3557, 1995.
4. Yoneda, T., Sasaki, A., Dunstan, C., Williams, P. J., Bauss, F., De Clerck, Y. A., and Mundy, G. R. Inhibition of osteolytic hone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Investig., 99: 2509-2517, 1997.
5. van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., and Papapoulos, S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Investig., 98: 698-705, 1996.
6. Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F. H., Delmas, P. D., and Clézardin, P. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res., 57: 3890-3894, 1997.
7. Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. G., and Croucher, P. I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br. J. Haematol., 98: 665-672, 1997.
8. Stearns, M. E., and Wang M. Effects of alendronate and Taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis, 16: 116-131, 1996.
9. Stearns, M. E., and Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC3 ML cells in SCID mice. Clin. Exp. Metastasis, 16: 693-702, 1998.
10. Diel, I. J., Solomayer, E. F., Costa, S. D., Gollan, C., Goerner, R., Wallwierner, D., Kauffmann, M., and Bastert, G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med., 339: 357-363, 1998.
11. Magnetic, S., Bruno-Bossio, G., Voland, C., Lecerf, J., Lawler, J., Delmas. P., Silverstein, R. L., and Clézardin, P. CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. Cell. Biochem. Funct., 16: 211-221, 1998.
12. Clézardin, P., Serre, C. M., Trzeciak, M. C., Drouin, J., and Delmas, P. D. Thrombospondin binds to the surface of osteosarcoma cells and mediates platelet-osteosarcomacell interaction. Cancer Res., 51: 2621-2627, 1991.
13. Knight, C. G., Willenbrock, F., and Murphy, G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett., 296: 263-266, 1992.
14. Bae, S. N., Arand, G., Azzam, H., Pavasant, P., Torri, J., Frandsen, T. L., and Thompson, E. W. Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res. Treat., 24: 241-255, 1993.
15. Rogers, M. J., Watts, D. J., and Russell, R. G. G. Overview of bisphosphonates. Cancer (Phila.), 80: 1652-1660, 1997.
16. Birrkedal-Hansen, H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol., 7: 728-735, 1995.
17. van Beek, E. R., Löwik, C. W. G. M., Ebetino, F. H., and Papapoulos, S. E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone, 23: 437-442, 1998.
18. Ebetino, F. H., and Dansereau, S. M. Bisphosphonate antiresorptive structure-activity relationships. In: O. Bijvoet, H. A. Fleisch, R. E. Canfield, and G. Russell (eds.), Bisphosphonates on Bones, pp. 139-153. Amsterdam: Elsevier Science B. V., 1995.
19. Derenne, S., Amiot, M., Barillé, S., Collette, M., Robillard, N., Berthaud, P., Harousseau, J. L., and Bataille, R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res., 14: 2048-2056, 1999.
20. Löwik, C. W. G. M., van der Pluijm, G., van der Wee-Pals, L. J. A., Bloys van Treslong-De Groot, H., and Bijvoet, O. L. M. Migration and phenotypic transformation of osteoclasts precursors into mature osteoclasts: the effect of a bisphosphonate. J. Bone Miner. Res., 3: 185-192, 1988.
21. Blavier, L., and Delaissé, J. M. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J. Cell Sci., 108: 3649-3659, 1995.
22. Teronen, O., Konttinen, Y. T., Lindqvist, C., Salo, T., Ingman, T., Lauhio, A., Ding, Y., Santavirta, S., Valleala, H., and Sorsa, T. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif. Tissue Int., 61: 59-61, 1997.
23. Fisher, E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Massaarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., and Eszka, A. A. Alendronate mechanisms of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA, 96: 133-138, 1999.
24. van Beek, E., Löwik, C., van der Pluijm, G., and Papapoulos, S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res., 14: 722-729, 1999.